First National Bank of Omaha reduced its holdings in shares of Stryker Co. (NYSE:SYK) by 3.6% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 2,675 shares of the medical technology company’s stock after selling 100 shares during the quarter. First National Bank of Omaha’s holdings in Stryker were worth $528,000 as of its most recent filing with the SEC.
Several other large investors have also added to or reduced their stakes in SYK. YCG LLC boosted its position in shares of Stryker by 1.0% in the 1st quarter. YCG LLC now owns 8,559 shares of the medical technology company’s stock valued at $1,691,000 after purchasing an additional 83 shares during the period. Dearborn Partners LLC boosted its position in shares of Stryker by 4.3% in the 1st quarter. Dearborn Partners LLC now owns 95,917 shares of the medical technology company’s stock valued at $18,946,000 after purchasing an additional 3,982 shares during the period. Migdal Insurance & Financial Holdings Ltd. boosted its position in shares of Stryker by 67.6% in the 1st quarter. Migdal Insurance & Financial Holdings Ltd. now owns 3,462 shares of the medical technology company’s stock valued at $684,000 after purchasing an additional 1,396 shares during the period. Segment Wealth Management LLC boosted its position in shares of Stryker by 2.6% in the 1st quarter. Segment Wealth Management LLC now owns 21,753 shares of the medical technology company’s stock valued at $4,297,000 after purchasing an additional 555 shares during the period. Finally, Public Employees Retirement Association of Colorado boosted its position in shares of Stryker by 4.6% in the 1st quarter. Public Employees Retirement Association of Colorado now owns 62,573 shares of the medical technology company’s stock valued at $12,359,000 after purchasing an additional 2,726 shares during the period. 73.61% of the stock is owned by institutional investors and hedge funds.
A number of analysts recently issued reports on the company. Wells Fargo & Co upped their target price on Stryker from $214.00 to $219.00 and gave the company an “outperform” rating in a research report on Monday, April 1st. Zacks Investment Research cut Stryker from a “buy” rating to a “hold” rating in a research report on Friday, April 12th. BTIG Research upped their target price on Stryker to $211.00 and gave the company a “buy” rating in a research report on Monday, March 18th. Barclays upped their price objective on Stryker from $203.00 to $211.00 and gave the company an “overweight” rating in a research note on Monday, April 15th. Finally, JPMorgan Chase & Co. upped their price objective on Stryker from $200.00 to $215.00 and gave the company an “overweight” rating in a research note on Tuesday, March 19th. Seven investment analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. Stryker currently has an average rating of “Buy” and an average price target of $196.85.
Shares of SYK stock traded down $0.60 during trading hours on Wednesday, reaching $181.38. 1,017,946 shares of the company’s stock were exchanged, compared to its average volume of 1,353,091. The company has a market cap of $68.94 billion, a price-to-earnings ratio of 24.81, a price-to-earnings-growth ratio of 2.25 and a beta of 0.84. Stryker Co. has a 1 year low of $144.75 and a 1 year high of $199.85. The company has a current ratio of 2.12, a quick ratio of 1.30 and a debt-to-equity ratio of 0.68.
Stryker (NYSE:SYK) last issued its earnings results on Tuesday, April 23rd. The medical technology company reported $1.88 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.84 by $0.04. The business had revenue of $3.52 billion during the quarter, compared to the consensus estimate of $3.51 billion. Stryker had a return on equity of 26.72% and a net margin of 25.38%. The company’s revenue for the quarter was up 8.5% on a year-over-year basis. During the same period in the prior year, the business posted $1.68 EPS. On average, equities analysts forecast that Stryker Co. will post 8.15 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Wednesday, July 31st. Stockholders of record on Friday, June 28th will be paid a dividend of $0.52 per share. This represents a $2.08 dividend on an annualized basis and a dividend yield of 1.15%. The ex-dividend date of this dividend is Thursday, June 27th. Stryker’s dividend payout ratio (DPR) is 28.45%.
In related news, VP Yin C. Becker sold 15,240 shares of the company’s stock in a transaction that occurred on Thursday, March 21st. The stock was sold at an average price of $198.03, for a total value of $3,017,977.20. Following the sale, the vice president now owns 16,577 shares in the company, valued at approximately $3,282,743.31. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, VP Katherine Ann Owen sold 29,247 shares of the company’s stock in a transaction that occurred on Friday, March 8th. The stock was sold at an average price of $185.62, for a total value of $5,428,828.14. Following the completion of the sale, the vice president now owns 11,131 shares in the company, valued at approximately $2,066,136.22. The disclosure for this sale can be found here. Over the last three months, insiders have sold 111,550 shares of company stock valued at $21,376,317. Company insiders own 7.20% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “First National Bank of Omaha Cuts Holdings in Stryker Co. (SYK)” was first posted by Sundance Herald and is owned by of Sundance Herald. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. and international trademark and copyright law. The legal version of this piece of content can be viewed at https://sundanceherald.com/2019/05/29/first-national-bank-of-omaha-trims-holdings-in-stryker-co-syk.html.
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.
Featured Story: What is a balanced fund?
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.